Professor Naveed Sattar has new paper released in Lancet
Published: 20 May 2025
Paper is called Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial
Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial
Summary
Naveed Sattar co-led a paper on the muscle effects of tirzepatide, widely sold now in the UK as Mounjaro, the weight loss medicine. The muscle effects of these drugs have been of concern as most consider the loss of muscle mass as adverse effect of such medicines. However, this new paper suggests most of the muscle loss is to be expected as similar loss was seen with predicted weight change without the drugs. In addition, tirzepatide also lowered the amount of fat within muscle, much more so than predicted from weight change without these medicines. Such muscle fat reduction may improve how the muscles work. Overall, this paper will help reassure many that muscle loss is not necessarily meaningfully greater with these drugs than from weight loss from other methods. More physical functioning measures on these drugs are now needed to complement this work.
First published: 20 May 2025
<< News